Our data raise concerns about its hemostatic safety in high-risk populations: patients with coagulation factor deficiencies (e.g., factor VII or IX deficiency) or concurrent antithrombotic therapy (e.g., aspirin, which inhibits AA-mediated aggregation) may experience exacerbated bleeding26. The gene discussed is F7; the disease is complement factor I deficiency.